Dr Lalchand. Lab

Who are the top shareholders of the Dr Lalchand. Lab?

The top shareholder of Dr Lalchand Lab is Arjan Lal Chandani, with a 42.53% stake, followed by public shareholder Amit Charan at 5.08%. Individual investors own 45.68% of the company, with no institutional or pledged promoter holdings.

The top shareholders of Dr Lalchand Lab include Arjan Lal Chandani, who holds the largest stake at 42.53%. Following him, the highest public shareholder is Amit Charan, with a holding of 5.08%. Additionally, individual investors collectively own 45.68% of the company. Notably, there are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

how big is Dr Lalchand. Lab?

As of Jun 06, Dr Lalchandani Labs Ltd has a market capitalization of 6.00 Cr, classifying it as a Micro Cap company, with shareholder's funds of 9.54 Cr and total assets of 14.99 Cr; however, no recent financial data is available for the latest four quarters.

Market Cap: As of Jun 06, Dr Lalchandani Labs Ltd has a market capitalization of 6.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of Mar'24. The Shareholder's Funds are valued at 9.54 Cr, and the Total Assets amount to 14.99 Cr.

Who are in the management team of Dr Lalchand. Lab?

As of March 2022, the management team of Dr Lalchand Lab includes Arjan Lalchandani (Chairman & Managing Director), Mohit Lalchandani (Whole Time Director & CEO), Anchal Gupta (Executive Director & CFO), and independent directors Rajiv Handa and Prakash Jhuraney, along with director Swati Chandra.

As of March 2022, the management team of Dr Lalchand. Lab includes the following individuals:<BR><BR>1. Arjan Lalchandani - Chairman & Managing Director<BR>2. Mohit Lalchandani - Whole Time Director & CEO<BR>3. Anchal Gupta - Executive Director & CFO<BR>4. Rajiv Handa - Independent Director<BR>5. Prakash Jhuraney - Independent Director<BR>6. Swati Chandra - Director<BR><BR>These members play key roles in the governance and operational management of the company.

What does Dr Lalchand. Lab do?

Dr Lalchandani Labs Ltd provides pathology laboratory services and operates as a micro-cap company with a market cap of Rs 6 Cr. It was established in 2011 and transitioned to a limited company in 2017.

Overview: <BR>Dr Lalchandani Labs Ltd operates in the healthcare services industry, specifically providing pathology laboratory services, and is classified as a micro-cap company.<BR><BR>History: <BR>Dr Lalchandani Labs Ltd was originally incorporated as a partnership firm in New Delhi on 15 September 2011 under the name Dr. A Lalchandani Pathology Laboratories. The partnership was taken over by Dr Lalchandani Labs Ltd on 2nd August 2017, as per the agreement dated 31st August 2017. Revenue and profit data are not available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 6 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 6.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.11 <BR>Return on Equity: 4.40% <BR>Price to Book: 0.64<BR><BR>Contact Details: <BR>Address: M-20 Basement, Greater Kailash-1, New Delhi, 110048 <BR>Tel: 91-11-49057058 <BR>Email: info@lalchandanipathlab.com <BR>Website: http://www.lalchandanipathlab.com

Has Dr Lalchand. Lab declared dividend?

No Dividend History Available

Who are the peers of the Dr Lalchand. Lab?

Dr. Lalchand Lab's peers include Syngene Intl., Dr. Lal Pathlabs, and Metropolis Health, among others. It has average management risk and below-average growth, with a 1-year return of -42.86%, significantly lower than its peers.

Peers: The peers of Dr Lalchand. Lab are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Vimta Labs, and the rest. Average management risk is noted for Vimta Labs and Dr Lalchand. Lab, while Below Average management risk is seen at Suven Life Scie. In terms of Growth, Excellent growth is found at Vimta Labs, while Average growth is observed at Poly Medicure, Indegene, and the rest. Below Average growth is noted for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Dr Lalchand. Lab, and Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 161.15%, while Dr Lalchand. Lab has the lowest at -42.86%. This indicates that Dr Lalchand. Lab's performance is significantly lower than its peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Metropolis Healt, and Dr Lalchand. Lab.

What is the technical trend for Dr Lalchand. Lab?

As of June 2, 2025, Dr. Lalchand Lab's trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, with weekly indicators showing mild bullishness and monthly indicators remaining bearish.

As of 2 June 2025, the technical trend for Dr Lalchand. Lab has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The daily moving averages are mildly bearish, while the weekly Bollinger Bands are bullish, contrasting with the monthly Bollinger Bands that are mildly bearish. The KST shows a mildly bullish stance on the weekly chart but is bearish on the monthly. Dow Theory indicates no trend on the weekly and mildly bullish on the monthly. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from MACD and Bollinger Bands.

When is the next results date for Dr Lalchand. Lab?

Dr Lalchand. Lab will announce its results on 14 November 2025.

Dr Lalchand. Lab is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Dr Lalchand. Lab?

Dr Lalchand. Lab has experienced a decline in net sales and profitability, with total operating income dropping from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25, and profit before tax decreasing from 1.25 Cr to 0.40 Cr in the same period. Total assets and liabilities also decreased, while cash flow from operating activities remained stagnant, though a net cash inflow of 1.00 Cr was recorded in Mar'25.

Answer:<BR>The historical performance of Dr Lalchand. Lab shows a declining trend in net sales and profitability over the past few years, with a significant drop in total operating income from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. The operating profit margin has fluctuated, peaking at 28.9% in Mar'24 before falling to 23.37% in Mar'25. Profit before tax also saw a decline, moving from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax decreased from 0.93 Cr in Mar'22 to 0.42 Cr in Mar'25. The company’s total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, and total liabilities also saw a reduction from 18.12 Cr to 15.75 Cr in the same period. Cash flow from operating activities has been stagnant, with no inflow reported in the last two years, although there was a net cash inflow of 1.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Lalchand. Lab's financial performance has shown a notable decline in net sales, which decreased from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. This decline is reflected in the total operating income, which also fell significantly over the years. The operating profit margin peaked at 28.9% in Mar'24 but dropped to 23.37% in Mar'25, indicating challenges in maintaining profitability. Profit before tax decreased from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax followed a similar trend, moving from 0.93 Cr to 0.42 Cr. The company's total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, with total liabilities also reducing in the same timeframe. Cash flow from operating activities has remained stagnant, with no inflow in recent years, although a net cash inflow of 1.00 Cr was recorded in Mar'25, suggesting some improvement in liquidity.

Is Dr Lalchand. Lab overvalued or undervalued?

As of December 4, 2025, Dr Lalchand Lab's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 19.83, an EV to EBITDA of 8.75, and a Price to Book Value of 0.84, making it more affordable compared to peers like Max Healthcare and Apollo Hospitals, while also outperforming the Sensex with a year-to-date return of 13.73%.

As of 4 December 2025, the valuation grade for Dr Lalchand. Lab has moved from risky to attractive, indicating a significant improvement in its investment appeal. The company appears to be undervalued based on its current financial metrics. Notable ratios include a PE ratio of 19.83, an EV to EBITDA of 8.75, and a Price to Book Value of 0.84, which suggest that the stock is trading at a discount relative to its earnings and assets.<BR><BR>When compared to peers, Dr Lalchand. Lab's valuation stands out positively. For instance, Max Healthcare is classified as very expensive with a PE ratio of 74.46, while Apollo Hospitals, also attractive, has a PE of 61.81. This comparison highlights Dr Lalchand. Lab's relative affordability in the healthcare services sector. Additionally, the company's recent stock performance shows a year-to-date return of 13.73%, outperforming the Sensex's 9.12%, reinforcing the notion that it may be undervalued in the current market.

Why is Dr Lalchandani Labs Ltd falling/rising?

As of 26-Mar, Dr Lalchandani Labs Ltd's stock price is at 14.81, unchanged from the previous session, and has declined 28.83% year-to-date, underperforming the Sensex. The stock shows a bearish trend, trading below key moving averages, with reduced investor participation and negative sector performance.

As of 26-Mar, Dr Lalchandani Labs Ltd's stock price is currently at 14.81, showing no change from the previous trading session. The stock has been experiencing a downward trend, with a 1-week decline of 4.94% and a 1-month decline of 11.37%. Year-to-date, the stock has fallen by 28.83%, significantly underperforming the benchmark Sensex, which has decreased by 11.67% over the same period.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 2.54%. Additionally, the stock has shown erratic trading patterns, not trading on 5 out of the last 20 days. It is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend.<BR><BR>Investor participation has also declined, with delivery volume dropping by 39.02% compared to the 5-day average, indicating reduced interest from investors. The overall action in the Hospital & Healthcare Services sector has also been negative, with a decline of 2.37%. These factors collectively contribute to the stock's falling price.

Why is Dr Lalchandani Labs Ltd falling/rising?

As of 27-Mar, Dr Lalchandani Labs Ltd's stock price is at 14.81, unchanged from the previous session, and has declined significantly by 28.83% year-to-date, underperforming the Sensex. The stock shows bearish trends with low trading activity and declining investor participation, reflecting negative market sentiment.

As of 27-Mar, Dr Lalchandani Labs Ltd's stock price is currently at 14.81, with no change from the previous trading session. The stock has shown a significant decline over various time periods, including a year-to-date drop of 28.83%, which is notably worse than the Sensex's decline of 13.66% during the same period. Over the past month, the stock has decreased by 6.74%, while the Sensex has fallen by 9.48%. <BR><BR>Today, the stock has underperformed its sector by 2.54%, indicating a weaker performance relative to its peers. Additionally, the stock has not traded on 5 out of the last 20 days, suggesting erratic trading behavior. It is also trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically indicates a bearish trend. <BR><BR>Investor participation appears to be declining, as evidenced by a 39.02% drop in delivery volume compared to the 5-day average. Furthermore, the broader Hospital & Healthcare Services sector has experienced a decline of 2.37%. These factors collectively contribute to the stock's falling price, reflecting a lack of investor confidence and overall negative market sentiment.

Why is Dr Lalchandani Labs Ltd falling/rising?

As of 28-Mar, Dr Lalchandani Labs Ltd's stock price is at 14.81, unchanged from the previous session, and has declined significantly by 28.83% year-to-date. The stock is underperforming its sector and trading below all moving averages, indicating a consistent downward trend and declining investor participation.

As of 28-Mar, Dr Lalchandani Labs Ltd's stock price is currently at 14.81, showing no change from the previous trading session. The stock has been experiencing a downward trend, as evidenced by its performance over various periods. Over the past week, the stock has fallen by 4.94%, and in the last month, it has decreased by 6.74%. Year-to-date, the decline is even more significant at 28.83%, compared to a lesser drop of 13.66% in the benchmark Sensex.<BR><BR>The stock's performance today indicates it has underperformed its sector by 2.54%. Additionally, the stock has shown erratic trading behavior, not trading on 5 out of the last 20 days. It is also trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a consistent downward trend in price.<BR><BR>Investor participation appears to be declining, with delivery volume on 04 March falling by 39.02% compared to the 5-day average. Furthermore, the overall sector, Hospital & Healthcare Services, has also seen a decline of 2.37%. These factors collectively contribute to the stock's falling price, reflecting a challenging environment for Dr Lalchandani Labs Ltd.

Why is Dr Lalchandani Labs Ltd falling/rising?

As of 29-Mar, Dr Lalchandani Labs Ltd's stock price is at 14.81, unchanged from the previous session, and has shown a downward trend with a 28.83% year-to-date decline, significantly underperforming the Sensex. The stock is trading below all key moving averages and has seen a 39.02% drop in delivery volume, reflecting reduced investor interest.

As of 29-Mar, Dr Lalchandani Labs Ltd's stock price is currently at 14.81, showing no change from the previous trading session. The stock has been experiencing a downward trend, as evidenced by its performance over various periods. Over the last week, the stock has declined by 4.94%, and it has fallen 6.74% over the past month. Year-to-date, the stock is down 28.83%, significantly underperforming the benchmark Sensex, which has only decreased by 13.66% in the same timeframe.<BR><BR>Additionally, the stock has underperformed its sector by 2.54% today and has shown erratic trading patterns, not trading on 5 out of the last 20 days. It is also trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Furthermore, there has been a notable decline in investor participation, with delivery volume dropping by 39.02% compared to the 5-day average. The overall action in the Hospital & Healthcare Services sector has also been negative, with a decline of 2.37%. These factors collectively contribute to the stock's falling price.

Which are the latest news on Dr Lalchand. Lab?

Which are the latest news on Dr Lalchand. Lab?

Which are the latest news on Dr Lalchand. Lab?